Anti-FGF 23 antibody

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Fibroblast Growth Factor 23 also known as FGF 23 is a hormone-like protein that plays a role in phosphate and vitamin D metabolism. It is a member of the fibroblast growth factor family and consists of about 251 amino acids with a mass of approximately 32 kDa. FGF 23 is predominantly expressed in bone cells especially osteocytes but it also appears in other tissues such as the thymus and brain. An important tool for quantitative measurement of FGF 23 levels is the FGF 23 ELISA kit which assists in various research and clinical settings.

Biological function summary

FGF 23 plays an important role in regulating phosphate balance in the body. It impacts the function of kidneys by decreasing the reabsorption of phosphate and suppressing the formation of active vitamin D thereby affecting calcium regulation as well. FGF 23 does not operate alone but interacts with co-receptors such as Klotho to activate its receptor complex. The protein functions as part of a larger system that fine-tunes the balance of minerals important for maintaining bone health and metabolic functions.

Pathways

FGF 23 is part of the bone-mineral metabolism axis and is integral to the phosphate regulation pathway. It works closely with proteins like Klotho and FGFR1 and their interaction ensures proper signaling required for maintaining serum phosphate levels. FGF 23 controls vitamin D metabolism by regulating the expression of 1-alpha-hydroxylase and 24-hydroxylase influencing the activity of the related vitamin D endocrine system. Its actions help stabilize phosphate and vitamin D status which are both essential for skeletal and mineral homeostasis.

Associated diseases and disorders

FGF 23 has a significant connection to conditions such as Hypophosphatemic Rickets and Chronic Kidney Disease (CKD). In these cases FGF 23 levels may become dysregulated leading to abnormal phosphate metabolism and bone mineralization defects. In Hypophosphatemic Rickets altered expression of FGF 23 causes excessive phosphate wasting whereas in CKD increased FGF 23 levels are associated with cardiovascular disease risk and deteriorating kidney function. Klotho as a coreceptor for FGF 23 also influences these pathological conditions highlighting its contribution to phosphate-related disorder mechanisms.